ALNYLAM PHARMACEUTICALS, INC. Financials Alnylam Pharmaceuticals, Inc. Börse Stuttgart
Equities
DUL
US02043Q1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
After market 04:00:02 pm | |||
| 229.9 EUR | -2.75% |
|
229.1 | -0.35% |
| Jul. 15 | Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing | MT |
| Jul. 03 | Jerome Powell did it again |  |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,840 | 15,100 | 20,282 | 29,238 | 24,021 | 32,405 | - | - |
| Enterprise Value (EV) 1 | 12,293 | 13,417 | 18,522 | 28,132 | 23,979 | 31,282 | 31,812 | 31,082 |
| P/E ratio | -14.2 x | -17.4 x | -23.6 x | -25.6 x | -54.4 x | -71.9 x | -165 x | 109 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 58.4 x | 30.6 x | 24 x | 28.2 x | 13.1 x | 17.3 x | 14 x | 10.5 x |
| EV / Revenue | 55.9 x | 27.2 x | 21.9 x | 27.1 x | 13.1 x | 16.7 x | 13.8 x | 10.1 x |
| EV / EBITDA | -13.9 x | -16.9 x | -28 x | -38 x | - | -97.2 x | 4,221 x | 40.6 x |
| EV / FCF | -29.4 x | -19.6 x | -25.8 x | -45.9 x | 572 x | -105 x | 4,114 x | 44.5 x |
| FCF Yield | -3.41% | -5.11% | -3.88% | -2.18% | 0.17% | -0.95% | 0.02% | 2.25% |
| Price to Book | 8.98 x | 14.9 x | 34.6 x | -186 x | -109 x | -285 x | -270 x | 70.4 x |
| Nbr of stocks (in thousands) | 111,490 | 116,181 | 119,601 | 123,028 | 125,493 | 126,492 | - | - |
| Reference price 2 | 115.2 | 130.0 | 169.6 | 237.6 | 191.4 | 256.2 | 256.2 | 256.2 |
| Announcement Date | 2/6/20 | 2/11/21 | 2/10/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 219.8 | 492.9 | 844.3 | 1,037 | 1,828 | 1,877 | 2,313 | 3,084 |
| EBITDA 1 | -885.1 | -793.7 | -661.1 | -740.6 | - | -321.9 | 7.537 | 765.3 |
| EBIT 1 | -939.4 | -828.4 | -708.7 | -785.1 | -282.2 | -370.6 | -156.4 | 380.4 |
| Operating Margin | -427.5% | -168.09% | -83.93% | -75.68% | -15.43% | -19.75% | -6.76% | 12.33% |
| Earnings before Tax (EBT) 1 | -885.3 | -855.6 | -852.1 | -1,127 | -433.5 | -461.3 | -217.4 | 297.5 |
| Net income 1 | -886.1 | -858.3 | -852.8 | -1,131 | -440.2 | -453.2 | -213.4 | 306 |
| Net margin | -403.24% | -174.15% | -101.01% | -109.04% | -24.08% | -24.15% | -9.22% | 9.92% |
| EPS 2 | -8.110 | -7.460 | -7.200 | -9.300 | -3.520 | -3.564 | -1.551 | 2.355 |
| Free Cash Flow 1 | -418.6 | -685.3 | -718.1 | -613.3 | 41.94 | -296.8 | 7.733 | 698.7 |
| FCF margin | -190.48% | -139.05% | -85.05% | -59.12% | 2.29% | -15.82% | 0.33% | 22.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 102.6% | 91.3% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 228.35% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/11/21 | 2/10/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 258.5 | 213.3 | 224.8 | 264.3 | 335 | 319.3 | 318.8 | 750.5 | 439.7 | 494.3 | 446.1 | 460 | 470 | 496.9 | 527.8 |
| EBITDA 1 | -183.2 | -137.3 | -181.6 | -247.4 | -174.3 | -135.7 | -216.7 | 227.2 | - | -29.92 | -114.5 | -79.7 | -56.9 | - | - |
| EBIT 1 | -194.6 | -146.7 | -191.7 | -258 | -188.6 | -149.8 | -229.8 | 213.9 | -116.4 | -43.44 | -114.2 | -112.1 | -113.4 | -104.2 | -106.4 |
| Operating Margin | -75.26% | -68.8% | -85.26% | -97.63% | -56.3% | -46.92% | -72.1% | 28.5% | -26.47% | -8.79% | -25.6% | -24.37% | -24.13% | -20.98% | -20.15% |
| Earnings before Tax (EBT) 1 | -260.3 | -239.4 | -274.7 | -405.9 | -207 | -172.4 | -274.2 | 150.7 | -137.7 | -63.59 | -136.1 | -139.3 | -141.1 | -122.4 | -132.9 |
| Net income 1 | -258.5 | -240.3 | -277.4 | -405.9 | -207.5 | -174.1 | -276 | 147.8 | -137.9 | -65.94 | -135.8 | -135.6 | -143.2 | -124.2 | -134.8 |
| Net margin | -99.97% | -112.7% | -123.39% | -153.58% | -61.93% | -54.53% | -86.59% | 19.69% | -31.35% | -13.34% | -30.45% | -29.48% | -30.48% | -25% | -25.54% |
| EPS 2 | -2.160 | -2.000 | -2.290 | -3.320 | -1.680 | -1.400 | -2.210 | 1.180 | -1.100 | -0.5200 | -1.093 | -1.048 | -1.070 | -0.9488 | -0.8806 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/10/22 | 4/28/22 | 7/28/22 | 10/27/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/15/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 547 | 1,683 | 1,760 | 1,105 | 41.4 | 1,123 | 593 | 1,323 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -419 | -685 | -718 | -613 | 41.9 | -297 | 7.73 | 699 |
| ROE (net income / shareholders' equity) | -53.4% | -69.9% | -106% | -526% | - | -180% | -4.02% | 71.3% |
| ROA (Net income/ Total Assets) | -44.6% | -29.6% | -24.2% | -31.5% | -11.9% | -7.49% | -5.53% | 1.15% |
| Assets 1 | 1,985 | 2,901 | 3,525 | 3,595 | 3,688 | 6,049 | 3,858 | 26,616 |
| Book Value Per Share 2 | 12.80 | 8.730 | 4.890 | -1.280 | -1.750 | -0.9000 | -0.9500 | 3.640 |
| Cash Flow per Share 2 | - | -5.350 | -5.420 | -4.450 | 0.8300 | -1.070 | 2.640 | 5.910 |
| Capex 1 | 140 | 70.4 | 76.4 | 72.1 | 62.2 | 64.9 | 88.3 | 127 |
| Capex / Sales | 63.78% | 14.28% | 9.05% | 6.95% | 3.4% | 3.46% | 3.82% | 4.1% |
| Announcement Date | 2/6/20 | 2/11/21 | 2/10/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
256.2
USD
Average target price
254.6
USD
Spread / Average Target
-0.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 46.56B | |
| +45.38% | 41.67B | |
| +0.69% | 41.16B | |
| +22.30% | 28.18B | |
| -6.35% | 28.1B | |
| +49.25% | 14.52B | |
| +49.18% | 13.74B | |
| +3.45% | 12.17B | |
| -3.85% | 11.14B |
- Stock Market
- Equities
- ALNY Stock
- DUL Stock
- Financials Alnylam Pharmaceuticals, Inc.
